Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,739   +0,001   (+0,14%) Dagrange 0,732 - 0,749 3.369.117   Gem. (3M) 4,8M

Pharming November 2020

10.131 Posts
Pagina: «« 1 ... 339 340 341 342 343 ... 507 »» | Laatste | Omlaag ↓
  1. forum rang 4 De Zwarte kat 23 november 2020 19:50
    quote:

    La Reina schreef op 23 november 2020 19:42:

    [...]
    Doe es normaal. En als dat niet lukt, zoek zelf eens iets op voordat u met dit soort krachttermen zwaait.Winstgevend had de link gewoon geplaatst.

    Hierbij de link: angioedemanews.com/2020/02/20/rucones...

    Zou maar gauw mijn excuses aan de poster aanbieden. Suc6!
    sorry ik bedoelde oud nieuws
  2. forum rang 8 BassieNL 23 november 2020 20:00
    quote:

    Winst gevend schreef op 23 november 2020 19:03:

    A total of 544 acute attacks in 21 HAE patients were treated on demand with Ruconest.

    Of those,
    240 attacks were subcutaneous (under the skin);
    231 were submucosal (under the mucosa),
    217 of those gastrointestinal
    014 of those under the upper airway;
    073 attacks were in other locations.

    Ruconest was given a median of 90 minutes after the attacks started,
    and symptoms began to ease as soon as 60 minutes later,
    fully resolving a median of 730 minutes (about 12 hours) after treatment.

    No severe or local allergic reactions or other severe side effects were reported.
    Wat vind je zo interessant aan dit oude bericht?
  3. forum rang 4 Kompas 23 november 2020 20:12
    quote:

    sintNL schreef op 23 november 2020 19:51:

    @Reina op het Galapagos forum, over bestuurders aan- en verkopen:

    Bij onze NL parel Pharming vinden zowel aankopen al verkopen plaats. De afgelopen 12 maanden voor 1.344.427,74 EUR aangekocht tegen over verkocht voor 975.000,00 EUR.

    Kun je die aankopen toelichten?

    Zeg eens beste Sint, eerder heb ik jou ook gevraagd of je persoonlijk nog een positie hebt in Pharming, zoals je in mijn herinnering eerder ooit aangaf een "kleine stad" (inwoners) aan aandelen Pharming te bezitten (BassieNL dan toch).

    Bij vragen stellen aan anderen is het dan ook zo aardig om aan jezelf gestelde vragen ook te beantwoorden lijkt me.
  4. forum rang 8 BassieNL 23 november 2020 20:16
    quote:

    Kompas schreef op 23 november 2020 20:12:

    [...]

    Zeg eens beste Sint, eerder heb ik jou ook gevraagd of je persoonlijk nog een positie hebt in Pharming, zoals je in mijn herinnering eerder ooit aangaf een "kleine stad" (inwoners) aan aandelen Pharming te bezitten (BassieNL dan toch).

    Bij vragen stellen aan anderen is het dan ook zo aardig om aan jezelf gestelde vragen ook te beantwoorden lijkt me.
    Ik heb aandelen Pharming Groep. Over het aantal aandelen heb ik me nooit uitgelaten. Dat vind ik niet chique.
  5. forum rang 7 Janssen&Janssen 23 november 2020 20:21
    Ik kom steeds meer onderzoeken tegen dat covid AKI triggert en dat mensen daar veel aan sterven.
    Het zijn niet de minste onderzoeken als ik ze zo lees. zou het niet kunnen zijn dat Osthoff een legale achterdeur heeft gevonden om zijn AKI studie in 1x mee af te ronden. of in ieder geval hele grootte stappen in te zetten?

    jasn.asnjournals.org/content/early/20...

    www.karger.com/Article/FullText/511161

    www.nature.com/articles/s41581-020-00...

  6. [verwijderd] 23 november 2020 20:21
    quote:

    van Buren schreef op 23 november 2020 13:55:

    Voor de zoveelste maal. Hier in Nederland wordt Nederlands gesproken en geschreven !
    angioedemanews.com/2020/10/30/first-d...

    The first documented case of a hereditary angioedema (HAE) attack in an unborn child — whose symptoms resolved after treating the mother with the recombinant human C1-inhibitor (rhC1-INH) therapy, Ruconest — has been reported.

    The case report, “Hereditary Angioedema Attack in Utero and Treatment of the Mother and Fetus,” was published in Mayo Clinic Proceedings: Innovations, Quality & Outcomes.

    HAE is most often caused by a mutation in the gene that codes for the protein C1 esterase inhibitor (C1-INH). The lack of functional C1-INH  leads to the swelling attacks characteristic of the disease.

    Growing evidence suggests that, during pregnancy, changes in hormone levels can influence the frequency and severity of HAE attacks. Some studies suggest that HAE attacks affecting the abdomen become more common when a person is pregnant; findings have indicated a higher risk of attacks in late stages of pregnancy when the fetus can also have HAE. But research is still quite preliminary.
    The report details a woman who first started experiencing HAE symptoms at age 12, and was diagnosed with HAE in 2015 at age 21. That year, she experienced 19 recorded HAE attacks; the following year, she had 14 attacks. The patient received acute treatment for these attacks, and was not on long-term prophylaxis.

    At 23, the woman became pregnant for the first time. Over the three trimesters of the pregnancy, she experienced a total of 30 HAE attacks.

    “For the mother, the number of HAE attacks during pregnancy was higher than before pregnancy, which is consistent with data from other studies,” the investigators wrote. Both are doctors; one is with a university dermatology clinic in North Macedonia, the other is with Pharming, which markets Ruconest.
    Late in her pregnancy, the 38th week, the woman experienced a HAE attack that started in the lower lip and spread across her face. She took Ruconest, and her symptoms started to improve after about 15 minutes.

    About 10 minutes after treating this attack, however, the patient felt unusual discomfort in her abdomen — the sensation was described as distinct from abdominal HAE attacks, and she didn’t feel nauseated or bloated. Concerned for the health of the fetus, the woman contacted her healthcare providers, and she was advised to go to the hospital for examination.

    At the hospital, ultrasound revealed that the fetus had substantial swelling of the lip (to roughly three times normal size) and the right thigh (exact measurements not recorded).

    A physical exam given the mother revealed that she was already in the late stages of labor.

    Roughly two hours after treating her HAE attack, the woman gave birth to a healthy male infant. The baby’s facial swelling completely resolved within two minutes of being born. The circumference of his right thigh was 25 mm larger than that of the left thigh, but this swelling resolved within half an hour of his birth.

    About 10 minutes after giving birth, the mother’s facial attack had almost completely resolved, and she did not experience subsequent attacks over the next several days.

    Genetic testing later confirmed that the infant has HAE.

    “This is the first documented case of an HAE attack in a fetus,” the researchers wrote. “Treatment of the mother with rhC1-INH was effective for both maternal and fetal attacks, which occurred almost simultaneously, with resolution within approximately 2 to 2.5 hours for both patients.”

    The fact that treatment affected not just the mother, but also her unborn child, is of note because biological processes regulate what substances from a pregnant person’s bloodstream can cross into the fetus’ blood supply.

    It is unknown whether rhC1-INH, used for treatment in this case, can cross these barriers. It is possible this is exactly what happened in this case.

    But, since the woman was likely in labor when she treated her attack, it is also possible that “rhC1-INH may have entered the fetal circulation with the rupture of the amniotic sac and disruption of the placenta,” the researchers suggested.
    Further studies will be needed to clarify this, but “the present findings suggest that active transport across the placental barrier should not be ruled out,” the team wrote.

    Importantly, the woman’s case shows it is possible for a fetus to have an HAE attack.

    “Ultrasonographers and neonatologists should consider the possibility of HAE in utero and immediately after birth when considering possible causes of fetal or neonatal edema,” the investigators concluded. “These data reinforce that it is imperative that newborns be tested as soon as possible if fetal edema via ultrasound is observed, particularly in those with a family history of HAE.”
    Regards,

    Jesse Livermore
  7. forum rang 4 Kompas 23 november 2020 20:26
    quote:

    sintNL schreef op 23 november 2020 20:16:

    [...]
    Ik heb aandelen Pharming Groep. Over het aantal aandelen heb ik me nooit uitgelaten. Dat vind ik niet chique.

    Ok, helder. Ik refereerde daarmee ook naar een beeldspraak welke in mijn herinnering eerder weleens voorbij is gekomen hier op het forum in een forumgesprek met jouzelf. Verder doet het er inderdaad ook niet toe. Maar gevoelsmatig ben je in de laatste maanden wat kritischer geworden, en ik vroeg mij gewoonweg af of dit mogelijk ook met een deels gewijzigde positie te maken zou kunnen hebben.
    That's all
  8. börse.de 23 november 2020 20:28
    quote:

    Jesse L. Livermore schreef op 23 november 2020 20:21:

    [...]

    angioedemanews.com/2020/10/30/first-d...

    The first documented case of a hereditary angioedema (HAE) attack in an unborn child — whose symptoms resolved after treating the mother with the recombinant human C1-inhibitor (rhC1-INH) therapy, Ruconest — has been reported.

    The case report, “Hereditary Angioedema Attack in Utero and Treatment of the Mother and Fetus,” was published in Mayo Clinic Proceedings: Innovations, Quality & Outcomes.

    HAE is most often caused by a mutation in the gene that codes for the protein C1 esterase inhibitor (C1-INH). The lack of functional C1-INH  leads to the swelling attacks characteristic of the disease.

    Growing evidence suggests that, during pregnancy, changes in hormone levels can influence the frequency and severity of HAE attacks. Some studies suggest that HAE attacks affecting the abdomen become more common when a person is pregnant; findings have indicated a higher risk of attacks in late stages of pregnancy when the fetus can also have HAE. But research is still quite preliminary.
    The report details a woman who first started experiencing HAE symptoms at age 12, and was diagnosed with HAE in 2015 at age 21. That year, she experienced 19 recorded HAE attacks; the following year, she had 14 attacks. The patient received acute treatment for these attacks, and was not on long-term prophylaxis.

    At 23, the woman became pregnant for the first time. Over the three trimesters of the pregnancy, she experienced a total of 30 HAE attacks.

    “For the mother, the number of HAE attacks during pregnancy was higher than before pregnancy, which is consistent with data from other studies,” the investigators wrote. Both are doctors; one is with a university dermatology clinic in North Macedonia, the other is with Pharming, which markets Ruconest.
    Late in her pregnancy, the 38th week, the woman experienced a HAE attack that started in the lower lip and spread across her face. She took Ruconest, and her symptoms started to improve after about 15 minutes.

    About 10 minutes after treating this attack, however, the patient felt unusual discomfort in her abdomen — the sensation was described as distinct from abdominal HAE attacks, and she didn’t feel nauseated or bloated. Concerned for the health of the fetus, the woman contacted her healthcare providers, and she was advised to go to the hospital for examination.

    At the hospital, ultrasound revealed that the fetus had substantial swelling of the lip (to roughly three times normal size) and the right thigh (exact measurements not recorded).

    A physical exam given the mother revealed that she was already in the late stages of labor.

    Roughly two hours after treating her HAE attack, the woman gave birth to a healthy male infant. The baby’s facial swelling completely resolved within two minutes of being born. The circumference of his right thigh was 25 mm larger than that of the left thigh, but this swelling resolved within half an hour of his birth.

    About 10 minutes after giving birth, the mother’s facial attack had almost completely resolved, and she did not experience subsequent attacks over the next several days.

    Genetic testing later confirmed that the infant has HAE.

    “This is the first documented case of an HAE attack in a fetus,” the researchers wrote. “Treatment of the mother with rhC1-INH was effective for both maternal and fetal attacks, which occurred almost simultaneously, with resolution within approximately 2 to 2.5 hours for both patients.”

    The fact that treatment affected not just the mother, but also her unborn child, is of note because biological processes regulate what substances from a pregnant person’s bloodstream can cross into the fetus’ blood supply.

    It is unknown whether rhC1-INH, used for treatment in this case, can cross these barriers. It is possible this is exactly what happened in this case.

    But, since the woman was likely in labor when she treated her attack, it is also possible that “rhC1-INH may have entered the fetal circulation with the rupture of the amniotic sac and disruption of the placenta,” the researchers suggested.
    Further studies will be needed to clarify this, but “the present findings suggest that active transport across the placental barrier should not be ruled out,” the team wrote.

    Importantly, the woman’s case shows it is possible for a fetus to have an HAE attack.

    “Ultrasonographers and neonatologists should consider the possibility of HAE in utero and immediately after birth when considering possible causes of fetal or neonatal edema,” the investigators concluded. “These data reinforce that it is imperative that newborns be tested as soon as possible if fetal edema via ultrasound is observed, particularly in those with a family history of HAE.”
    Regards,

    Jesse Livermore

    zo maak je meters op het forum; dit nieuws dateert van eind oktober....
  9. forum rang 8 BassieNL 23 november 2020 20:35
    quote:

    Kompas schreef op 23 november 2020 20:26:

    [...]

    Ok, helder. Ik refereerde daarmee ook naar een beeldspraak welke in mijn herinnering eerder weleens voorbij is gekomen hier op het forum in een forumgesprek met jouzelf. Verder doet het er inderdaad ook niet toe. Maar gevoelsmatig ben je in de laatste maanden wat kritischer geworden, en ik vroeg mij gewoonweg af of dit mogelijk ook met een deels gewijzigde positie te maken zou kunnen hebben.
    That's all
    Ik ben kritisch omdat ik me goed inlees. Dat zouden meer forumleden moeten doen. Dan zou er wat minder onzin worden geplaatst.
  10. [verwijderd] 23 november 2020 20:35
    quote:

    sintNL schreef op 23 november 2020 19:51:

    @Reina op het Galapagos forum, over bestuurders aan- en verkopen:

    Bij onze NL parel Pharming vinden zowel aankopen al verkopen plaats. De afgelopen 12 maanden voor 1.344.427,74 EUR aangekocht tegen over verkocht voor 975.000,00 EUR.

    Kun je die aankopen toelichten?

    Ik herhaal de vraag nog maar even. Anders mist La Reina de vraag misschien gezien de lappen tekst die hierna geknipt en geplakt zijn.

    Ik ben nl. ook wel benieuwd naar het antwoord.

    Goedenavond overigens
  11. [verwijderd] 23 november 2020 20:38
    Dat er beweging is achter de schermen lijkt langzamerhand duidelijker te worden.
    Vooral het benoemen van Mark Jerome Pykett blijft voor mij interessant.
    Net aangetreden bij PTC als CSO , en met de nodige bagage inzake gentherapie (o.a Rocket), krijgt hij een compleet kijkje in de handel en wandel van Pharming.
    En een CEO die tijdens de laatste twee webinars een opmerking maakte die op een insteek in die richting zou kunnen wijzen.
    Schmertzler en Pykett hebben achtereenvolgend bij dezelfde biotechbedrijven gewerkt.
    Je weet maar nooit.
    Zou zomaar eens een interessant '21 kunnen worden.
    Er blijft gelukkig veel te gissen.
  12. forum rang 8 BassieNL 23 november 2020 20:39
    quote:

    Eric de Rus schreef op 23 november 2020 20:35:

    [...]

    Ik herhaal de vraag nog maar even. Anders mist La Reina de vraag misschien gezien de lappen tekst die hierna geknipt en geplakt zijn.

    Ik ben nl. ook wel benieuwd naar het antwoord.

    Goedenavond overigens
    Hij zit toch niet opnieuw te jokkebrokken?
  13. forum rang 4 Kompas 23 november 2020 20:43
    quote:

    sintNL schreef op 23 november 2020 20:35:

    [...]
    Ik ben kritisch omdat ik me goed inlees. Dat zouden meer forumleden moeten doen. Dan zou er wat minder onzin worden geplaatst.

    Ik denk toch te kunnen stellen dat ik mijzelf ook goed inlees.
    Daarnaast ben en blijf ik vol vertrouwen en hoop over het algemeen dat men overwegend vindt dat ik hier weinig onzin plaats haha
10.131 Posts
Pagina: «« 1 ... 339 340 341 342 343 ... 507 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.